MINNEAPOLIS/ST. PAUL (December 19, 2016) – Unprecedented images of cancer genome-mutating enzymes acting on DNA provide vital clues into how the enzymes work to promote tumor evolution and drive poor disease outcomes. These images, revealed by University of Minnesota researchers, provide the first ever high-resolution pictures of molecular complexes formed between DNA and the human APOBEC3A and APOBEC3B enzymes.
A new study in JAMA Oncology finds that antibodies to human papillomavirus detectable in blood serum are reliable indicators of five-year head and neck cancer survival
MINNEAPOLIS/ST. PAUL (November 30, 2016) – Frequent genetic rearrangements in the androgen receptor could be limiting treatment options for prostate cancer patients, according to new research out of the University of Minnesota. Currently, the main treatment for prostate cancer inhibits androgen receptor activity. However, the new paper identified frequent rearrangements in the metastases of prostate cancer, allowing cancer cells to accumulate a variety of receptor forms and increasing resistance to treatments.
The annual event aims to spur new ideas and collaborations toward developing new cancer research
Recognition will help further research on exploring genetic connections to breast cancer
Discovery holds promise for improving treatment success for a variety of tumors
MINNEAPOLIS/SAINT PAUL (September 22, 2016) – David Masopust, Ph.D., has been named to the inaugural class of Howard Hughes Medical Institute (HHMI) Faculty Scholars, recognizing his dedication to creative and innovative solutions in science.
Reuben Harris and colleagues pinpoint an enzyme that causes mutation in tumor cells, opening door to novel therapies that limit the development of mutations
MINNEAPOLIS/ST. PAUL (9/21/16) — Researchers looking for a missing cause of a common type of mutation in breast cancer cells have uncovered the biochemical culprit and found that it may also be a general source of mutation in other cancer types.